Cover Image
市場調查報告書

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1:開發中產品分析

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363129
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
Corticosteroid 11-Beta-Dehydrogenase Isozyme 1:開發中產品分析 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2017
出版日期: 2017年10月10日 內容資訊: 英文 61 Pages
簡介

本報告提供Corticosteroid 11-Beta-Dehydrogenase Isozyme 1藥物的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1概要

治療藥的開發

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1:開發中的產品 - 各開發階段

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1:開發中的產品 - 治療範圍別

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1:開發中的產品 - 各適應症

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1:企業開發中的產品

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1:大學/機關開發中的產品

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1治療藥的開發企業

  • Actinogen Limited
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Connexios Life Sciences Pvt. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Hyundai Pharmaceutical Co., Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Poxel SA
  • Sanofi
  • Shanghai Pharmaceutical Co., Ltd.
  • SK Chemicals Co., Ltd.
  • 大日本住友製藥
  • Toray Industries

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1:藥物簡介

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1:暫停中的計劃

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1:中止開發的產品

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1042TDB

Summary:

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - 11beta-hydroxysteroid dehydrogenase type 1 is an NADPH-dependent enzyme highly expressed in key metabolic tissues including liver, adipose tissue, and the central nervous system. In these tissues HSD11B1 reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. This enzyme plays an important role in obesity and insulin resistance.

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 6 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Ophthalmology, Cardiovascular, Dermatology and Immunology which include indications Type 2 Diabetes, Obesity, Alzheimer's Disease, Glaucoma, Cardiomyopathy, Cushing's Syndrome, Dementia Associated With Alzheimer's Disease, Inflammation, Intracranial Hypertension, Metabolic Syndrome, Ocular Hypertension, Open-Angle Glaucoma, Osteopenia, Psychiatric Disorders and Wounds.

The latest report Corticosteroid 11 Beta Dehydrogenase Isozyme 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146)
  • The report reviews Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Overview
    • Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Companies Involved in Therapeutics Development
    • Actinogen Medical Ltd
    • Astellas Pharma Inc
    • AstraZeneca Plc
    • Boehringer Ingelheim GmbH
    • Connexios Life Sciences Pvt Ltd
    • F. Hoffmann-La Roche Ltd
    • Hyundai Pharmaceutical Co Ltd
    • Laboratorios SALVAT SA
    • Poxel SA
    • SK Chemicals Co Ltd
    • Toray Industries Inc
  • Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Drug Profiles
    • ASP-3662 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-4017 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-135558 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CNX-1049 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIS-388 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-046 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KR-66344 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCE-402 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-5093151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase 1 for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SVT-63 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SVT-88 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TR-013A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UE-2343 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Dormant Products
  • Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Discontinued Products
  • Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 07, 2017: Actinogen Medical: First patient completes landmark Alzheimer's disease trial
      • Aug 16, 2017: First UK patient treated in ground-breaking Alzheimer's clinical trial
      • Jul 26, 2017: Actinogen Medical Provides Update on Xanamem
      • Jun 22, 2017: First US patients treated in landmark Alzheimers disease trial
      • Jun 01, 2017: First UK site goes live in global Alzheimer's disease clinical trial
      • May 16, 2017: First patient treated in landmark Alzheimer's disease clinical trial
      • Apr 26, 2017: Actinogen provides March quarterly update
      • Mar 08, 2017: TGA Regulatory Approval Received for Alzheimer's Phase II Trial
      • Feb 27, 2017: Actinogen announce Medical Half-Year Results
      • Feb 09, 2017: Xanamem research published in prestigious medical journal
      • Jan 10, 2017: UK Regulatory Approval for Alzheimer's Disease Clinical Trial - XanADu
      • Jan 03, 2017: FDA Approval to Commence Alzheimer's Disease Clinical Trial
      • Dec 19, 2016: Significant Advance In Development Of Actinogen Medical Alzheimer's Drug Xanamem
      • Dec 06, 2016: Actinogen Medical: Xanamem Research Presented At CTAD
      • Sep 29, 2016: FDA Feedback On Xanamem Alzheimers Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Actinogen Medical Ltd, H2 2017
  • Pipeline by Astellas Pharma Inc, H2 2017
  • Pipeline by AstraZeneca Plc, H2 2017
  • Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017
  • Pipeline by Laboratorios SALVAT SA, H2 2017
  • Pipeline by Poxel SA, H2 2017
  • Pipeline by SK Chemicals Co Ltd, H2 2017
  • Pipeline by Toray Industries Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top